• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation.

作者信息

Zhao Davidson, Rumina Musani, Zarif Mojgan, Wei Cuihong, Chang Hong

机构信息

Department of Laboratory Medicine and Pathobiology Temerty Faculty of Medicine University of Toronto Toronto Canada.

Department of Laboratory Hematology Laboratory Medicine Program University Health Network Toronto Canada.

出版信息

EJHaem. 2024 Nov 22;5(6):1370-1372. doi: 10.1002/jha2.1055. eCollection 2024 Dec.

DOI:10.1002/jha2.1055
PMID:39691238
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11647738/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c001/11647738/206baf8be150/JHA2-5-1370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c001/11647738/206baf8be150/JHA2-5-1370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c001/11647738/206baf8be150/JHA2-5-1370-g001.jpg

相似文献

1
Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation.伴有CEBPA突变的急性髓系白血病中继发类型突变的影响
EJHaem. 2024 Nov 22;5(6):1370-1372. doi: 10.1002/jha2.1055. eCollection 2024 Dec.
2
Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.CEBPA 基因突变和启动子超甲基化在小儿急性髓细胞白血病中的特征。
Haematologica. 2011 Mar;96(3):384-92. doi: 10.3324/haematol.2010.031336. Epub 2010 Dec 6.
3
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.急性髓系白血病患者的GATA2突变——配对样本分析表明，该突变在疾病演变过程中不稳定。
Ann Hematol. 2015 Feb;94(2):211-21. doi: 10.1007/s00277-014-2208-8. Epub 2014 Sep 21.
4
Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.正常核型急性髓系白血病中CEBPA基因突变的分子评估：两种方法的比较及印度急性髓系白血病患者新CEBPA基因突变报告
Genet Test Mol Biomarkers. 2012 Jul;16(7):707-15. doi: 10.1089/gtmb.2011.0317. Epub 2012 Jun 25.
5
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.CEBPA 突变对年轻急性髓系白血病患者大队列的预后意义：双 CEBPA 突变的影响以及与 FLT3 和 NPM1 突变的相互作用。
J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.
6
Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.CEBPA突变和BAALC表达在埃及核型正常的急性髓系白血病患者中的预后意义
Egypt J Immunol. 2008;15(1):131-43.
7
CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.CEBPA 单突变可能是中危细胞遗传学核型伴有 NPM1 和 FLT3-ITD 野生型急性髓系白血病患者的有利预后指标。
Leuk Res. 2013 Nov;37(11):1488-94. doi: 10.1016/j.leukres.2013.08.014. Epub 2013 Sep 5.
8
CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.埃及急性髓系白血病患者中的CEBPA基因突变：对预后的影响。
Hematology. 2013 Mar;18(2):61-8. doi: 10.1179/1607845412Y.0000000032. Epub 2012 Sep 14.
9
Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.CEBPA 突变型急性髓系白血病中 WT1 突变的频率及其临床影响。
Hematology. 2022 Dec;27(1):994-1002. doi: 10.1080/16078454.2022.2103964.
10
Germline CEBPA mutation in familial acute myeloid leukemia.家族性急性髓系白血病中的胚系CEBPA突变
Hematol Rep. 2021 Oct 4;13(3):9114. doi: 10.4081/hr.2021.9114. eCollection 2021 Sep 6.

本文引用的文献

1
Prognostic impact of CEBPA mutational subgroups in adult AML.CEBPA 突变亚组对成人 AML 的预后影响。
Leukemia. 2024 Feb;38(2):281-290. doi: 10.1038/s41375-024-02140-x. Epub 2024 Jan 16.
2
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.与 ELN 有利风险 NPM1 突变型 AML 中次级 AML 高度特异性的突变与不良预后相关。
Blood Adv. 2024 Mar 12;8(5):1075-1083. doi: 10.1182/bloodadvances.2023011173.
3
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
CEBPA 突变的 AML：20%以上原始细胞的 ICC 与 WHO-HAEM5 标准在患者中的比较。
Leuk Res. 2023 Nov;134:107376. doi: 10.1016/j.leukres.2023.107376. Epub 2023 Aug 29.
4
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.继发性类型突变不影响NPM1突变型急性髓系白血病的预后——对欧洲白血病网风险分类的意义
Leukemia. 2023 Nov;37(11):2282-2285. doi: 10.1038/s41375-023-02016-6. Epub 2023 Sep 7.
5
Impact of secondary-type mutations in NPM1 mutated AML.NPM1突变型急性髓系白血病中继发类型突变的影响
Eur J Haematol. 2023 Jul;111(1):165-168. doi: 10.1111/ejh.13979. Epub 2023 May 10.
6
Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.继发性突变不影响伴有NPM1突变的急性髓系白血病（AML）的预后。
Am J Hematol. 2022 Dec;97(12):E462-E465. doi: 10.1002/ajh.26730. Epub 2022 Sep 30.
7
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
8
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
9
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
10
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.基于 MDS 或 MDS/MPN 病史诊断的 NPM1 突变型 AML-MRC 常伴有继发性突变，与 NPM1 突变型 AML 相比预后较差。
Leuk Res. 2022 Jul;118:106869. doi: 10.1016/j.leukres.2022.106869. Epub 2022 May 22.